Gamida Cell Ltd Pharmaceuticals Healthcare: Ken Research
Gamida Cell Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Gamida Cell Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH7665D
  • |
  • Pages: 37
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Gamida Cell Ltd (Gamida) is a developer of cellular and immune therapeutics. The company's products comprise nicord, cordin and NK cell product. Its nicord is developed for the treatment of bone marrow transplantation for patients with high risk leukemia and lymphoma. Gamida's cordin is used for the treatment of non-malignant orphan diseases. The company uses its NAM technology platform and copper chelator based technology for its product development for cell therapy. It undertakes clinical studies for the treatment of blood cancers. The company serves patients with cancer and rare genetic diseases. Gamida is headquartered in Jerusalem, Israel.

Gamida Cell Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Gamida Cell Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Gamida Cell Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Gamida Cell Raises USD 10 Million In Series E Financing 11

Private Equity 13

Gamida Cell Raises USD40 Million in Private Financing 13

Acquisition 15

Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 15

Novartis to Acquire Additional 2.5% Stake in Gamida Cell for USD15 Million 16

Novartis Pharma Acquires 15% Stake in Gamida Cell for USD35 Million 17

Gamida Cell Ltd-Key Competitors 18

Gamida Cell Ltd-Key Employees 19

Gamida Cell Ltd-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Corporate Communications 21

Apr 26, 2018: Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing 21

Mar 15, 2018: Gamida Cell Appoints Shai Lankry as Chief Financial Officer 22

Nov 20, 2017: Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer 23

Jul 10, 2017: Gamida Cell announces joining of new CMO 24

Jun 05, 2017: Gamida Cell appoints two new board members 25

Product News 26

12/11/2017: Gamida Cell Presents Data from NiCord Development Program at the 2017 ASH Annual Meeting 26

11/01/2017: Gamida Cell to Present New On NiCord at 2017 ASH Annual Meeting 27

07/10/2017: Gamida Cell Names Ronit Simantov, M.D. as Chief Medical Officer 28

06/05/2017: Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors 29

04/20/2017: Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation 30

02/20/2018: Gamida Cell to Present Data from NiCord Programs at the 2018 BMT Tandem Meetings 31

Product Approvals 33

Mar 23, 2017: Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord in Haematopoietic Stem Cell Transplantation 33

Clinical Trials 34

Mar 19, 2018: Gamida Cell to Present Immune Reconstitution Data for its NiCord Program at the 2018 EBMT Annual Meeting 34

Jul 20, 2017: Gamida Cell Obtains USD 3.5 Million Israeli Grant, to Help Support Development of NiCord 35

Feb 28, 2017: Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37

List of Figures

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Gamida Cell Ltd, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Gamida Cell Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Gamida Cell Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Gamida Cell Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Gamida Cell Raises USD 10 Million In Series E Financing 11

Gamida Cell Raises USD40 Million in Private Financing 13

Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 15

Novartis to Acquire Additional 2.5% Stake in Gamida Cell for USD15 Million 16

Novartis Pharma Acquires 15% Stake in Gamida Cell for USD35 Million 17

Gamida Cell Ltd, Key Competitors 18

Gamida Cell Ltd, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Gamida Cell Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com